The DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Open accessAbstract
The development of early non-invasive diagnosis methods and identification of novel biomarkers are necessary for managing Alzheimer's disease (AD) and facilitating effective prognosis and treatment. AD has multi-factorial nature and involves complex molecular mechanism, which causes neuronal degeneration. The primary challenges in early AD detection include patient heterogeneity and lack of precise diagnosis at the preclinical stage. Several cerebrospinal fluid (CSF) and blood biomarkers have been proposed to show excellent diagnosis ability by identifying tau pathology and cerebral amyloid beta (Aβ) for AD. Intense research endeavors are being made to develop ultrasensitive detection techniques and find potent biomarkers for early AD diagnosis. To mitigate AD worldwide, understanding various CSF biomarkers, blood biomarkers, and techniques that can be used for early diagnosis is imperative. This review attempts to provide information regarding AD pathophysiology, genetic and non-genetic factors associated with AD, several potential blood and CSF biomarkers, like neurofilament light, neurogranin, Aβ, and tau, along with biomarkers under development for AD detection. Besides, numerous techniques, such as neuroimaging, spectroscopic techniques, biosensors, and neuroproteomics, which are being explored to aid early AD detection, have been discussed. The insights thus gained would help in finding potential biomarkers and suitable techniques for the accurate diagnosis of early AD…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blood biomarkers offer an economical, convenient, minimally invasive, and highly accessible diagnostic alternative.385–387”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [386]
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
Protein and polymer analyses up to m/z 100 000 by laser ionization time‐of‐flight mass spectrometry
Tanaka, K., Waki, H., Ido, Y., Akita, S., Yoshida, Y., Yoshida, T., & Matsuo, T. (1988) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1290020802 · Cited by 3,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Research works printed but not linked: 5
- Crist AM, Hinkle KM, Wang X et al (2020) A novel tau binding partner SERPINA5 Results Bulk transcriptional profiling of hippocampal vulnerability in AD. Springer, New York
- Hampel H, Lista S, Vanmechelen E et al (2020) β -Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification. Alzheimer’s Dis 3:1–14
- Kepp KP (2012) Bioinorganic chemistry of Alzheimer ’ s disease. Bioorg Chem 112:5193
- Lambert JC, Ibrahim-Verbaas CA, Harold D et al (2013b) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458. https://doi.org/10.1038/ng.2802 · DOI · Paper page
- Wilson MS, Metink-Kane MM (2012) 基因的改变NIH Public Access. Bone 23:1–7. https://doi.org/10.1146/annurev-statistics-022513-115611.Brain · doi:10.1146/annurev-statistics-022513-115611.brain
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Lin, R., Jin, L., Xue, Y., Zhang, Z., Huang, H., Chen, D., Liu, Q., Mao, Z., Wu, Z., & Tao, Q. (2024) · Advanced Science · doi:10.1002/advs.202306675 · Cited by 76
Maiese, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273570 · Cited by 53
“Tau seeding, also present in AD (7, 123, 311, 372 – 376), has been reported in the brains of MS patients (140) and this tau deposition may produce demyelination through injury to oligodendrocytes (128).”
BackgroundLiu, H., Yuan, X., Liu, T., Zhang, W., Dong, H., & Chu, Z. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304355 · Cited by 34
Cognitive Impairment in Multiple Sclerosis
Maiese, K. (2023) · Bioengineering · doi:10.3390/bioengineering10070871 · Cited by 38
Metadata
- Authors
- Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P.
- Affiliations
- Panjab University (IN)
- Texas A&M University (US)
- Corresponding author
- Rani, Shital
- Dhar, Sudhrita Basu
- Khajuria, Akhil
- Gupta, Dikshi
- Jaiswal, Pradeep Kumar
- Singla, Neha
- Kaur, Mandeep
- Singh, Gurpal
- Barnwal, Ravi Pratap
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2023-02-27
- Volume
- 43
- Issue
- 6
- Pages
- 2491-2523
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11410160
- OpenAlex
- W4322495020
- Cited by
- 48
- References
- 263
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 13 · 2023: 6
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Department of Biotechnology, Ministry of Science and Technology, India
- Indian Council of Medical Research
- Science and Engineering Research Board
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, early diagnosis, biomarkers, cerebrospinal fluid biomarkers, blood biomarkers, tau pathology, amyloid-beta, neurofilament light chain, neurogranin, neuroimaging, spectroscopic methods, biosensors, neuroproteomics, preclinical Alzheimer's disease, genetic risk factors, non-genetic risk factors
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease. https://app.cochat.ai/papers/10.1007/s10571-023-01330-y
- The paper
- Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023). Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-023-01330-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.